Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1307-1313

  Bueters, Tjerk J H ^a,b   Joosen, Marloes J A ^a   Van Helden, Herman P M ^a   Ijzerman, Ad P ^b   Danhof, Meindert ^b  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CYCLOPENTYLADENOSINE; ACETYLCHOLINESTERASE; ADENOSINE A1 RECEPTOR AGONIST; CHOLINESTERASE INHIBITOR; SARIN; ADENOSINE; ADENOSINE RECEPTOR; DRUG DERIVATIVE; N(6) CYCLOPENTYLADENOSINE; N(6)-CYCLOPENTYLADENOSINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME BLOOD LEVEL; ENZYME INACTIVATION; ENZYME LOCALIZATION; INHIBITION KINETICS; MALE; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SYMPTOMATOLOGY; ANIMAL; BIOLOGICAL MODEL; BLOOD; BRAIN; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; METABOLISM; TISSUE DISTRIBUTION; WISTAR RAT;

ACETYLCHOLINESTERASE; ADENOSINE; ANIMALS; BLOOD; BRAIN; CHOLINESTERASE INHIBITORS; DRUG INTERACTIONS; MALE; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P1; SARIN; TISSUE DISTRIBUTION;

EID: 0037332575     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044644     Document Type: Article

References (34)

1. 1 receptor-mediated inhibition of acetylcholine release with low efficacy agonists. Drug Dev Res 50:81.
2. 6-cyclopentyladenosine (CPA) against organophosphate poisoning. Arch Toxicol 76:650-656.
3. D'Agostino PA, Hancock JR, and Provost LR (1999) Packed capillary liquid chromatography-electrospray mass spectrometry analysis of organophosphorus chemical warfare agents. J Chromatogr A 840:289-294.
4. D'Agostino PA, Hancock JR, and Provost LR (2001) Determination of sarin, soman and their hydrolysis products in soil by packed capillary liquid chromatography-electrospray mass spectrometry. J Chromatogr A 912:291-299.
5. Ellman GL, Courtney KD, Andres P, and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88.
6. Fisher DM and Wright PM (1997) Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants? Anesthesiology 86:567-575.
7. Gabrielsson J, Jusko WJ, and Alari L (2000) Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos 21:41-52.
8. Gearhart JM, Jepson GW, Clewell HJ, Andersen ME, and Conolly RB (1994) Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. Environ Health Perspect 102 (Suppl 11):51-60.
9. Gupta RC, Patterson GT, and Dettbarn WD (1991) Comparison of cholinergic and neuromuscular toxicity following acute exposure to sarin and VX in rat. Fundam Appl Toxicol 16:449-458.
10. Hayward IJ, Wall HG, Jaax NK, Wade JV, Marlow DD, and Nold JB (1990) Decreased brain pathology in organophosphate-exposed rhesus monkeys following benzodiazepine therapy. J Neurol Sci 98:99-106.
11. Holstege CP, Kirk M, and Sidell FR (1997) Chemical warfare. Nerve agent poisoning. Crit Care Clin 13:923-942.
12. Johnson CD and Russell RL (1975) A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal Biochem 64:229-238.
13. Jokanovic M and Maksimovic M (1997) Abnormal cholinesterase activity: understanding and interpretation. Eur J Clin Chem Clin Biochem 35:11-16.
14. Jusko WJ (1971) Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 60:892-895.
15. Kadar T, Shapira S, Cohen G, Sahar R, Alkalay D, and Raveh L (1995) Sarin-induced neuropathology in rats. Hum Exp Toxicol 14:252-259.
16. 1 receptor in rat cerebral cortex. Neurosci Lett 209:181-184.
17. Lallement G, Clarencon D, Masqueliez C, Baubichon D, Galonnier M, Burckhart MF, Peoc'h M, and Mestries JC (1998) Nerve agent poisoning in primates: antilethal, anti-epileptic and neuroprotective effects of GK-11. Arch Toxicol 72:84-92.
18. Lotti M (1992) Central neurotoxicity and behavioural effects of acetylchalinesterases, in Clinical and Experimental Toxicology of Organophosphates and Carbamates (Ballantyne B and Marrs TC eds) pp 75-83, Butterworth-Heinemann, Oxford, UK.
19. Lotti M (1995) Cholinesterase inhibition: complexities in interpretation. Clin Chem 41:1814-1818.
20. Materi LM, Rasmusson DD, and Semba K (2000) Inhibition of synaptically evoked cortical acetylcholine release by adenosine: an in vivo microdialysis study in the rat. Neuroscience 97:219-226.
21. 6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther 268:616-624.
22. Nigg HN and Knaak JB (2000) Blood cholinesterases as human biomarkers of organophosphorus pesticide exposure. Rev Environ Contain Toxicol 163:29-111.
23. Pardridge WM, Yoshikawa T, Kang YS, and Miller LP (1994) Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Pharmacol Exp Ther 268:14-18.
24. Pavan B and IJzerman AP (1998) Processing of adenosine receptor agonists in rat and human whole blood. Biochem Pharmacol 56:1625-1632.
25. Shih TM and McDonough JH Jr (1997) Neurochemical mechanisms in soman-induced seizures. J Appl Toxicol 17:255-264.
26. Spruit HE, Langenberg JP, Trap HC, Van der Wiel HJ, Helmich RB, van Helden HP, and Benschop HP (2000) Intravenous and inhalation toxicokinetics of sarin stereoisomers in atropinized guinea pigs. Toxicol Appl Pharmacol 169:249-254.
27. Spruit HE, Trap HC, Langenberg JP, and Benschop HP (2001) Bioanalysis of the enantiomers of (±)-sarin using automated thermal cold-trap injection combined with two-dimensional gas chromatography. J Anal Toxicol 25:57-61.
28. Tripathi HL and Dewey WL (1989) Comparison of the effects of diisopropylfluorophosphate, sarin, soman and tabun on toxicity and brain acetylcholinesterase activity in mice. J Toxicol Environ Health 26:437-446.
29. Van Helden HP and Bueters TJ (1999) Protective activity of adenosine receptor agonists in the treatment of organophosphate poisoning. Trends Pharmacol Sci 20:438-441.
30. Van Helden HP, Busker RW, Melchers BP, and Bruijnzeel PL (1996) Pharmacological effects of oximes: how relevant are they? Arch Toxicol 70:779-786.
31. Van Helden HP, Groen B, Moor E, Westerink BH, and Bruijnzeel PL (1998) New generic approach to the treatment of organophosphate poisoning: adenosine receptor mediated inhibition of ACh-release. Drug Chem Toxicol 21 (Suppl 1):171-181.
32. 6- cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. Br J Pharmacol 124:607-618.
33. Wenthold RJ, Mahler HR, and Moore WJ (1974) The half-life of acetylcholinesterase in mature rat brain. J Neurochem 22:941-943.
34. Yano I, Beal SL, and Sheiner LB (2001) The need for mixed-effects modeling with population dichotomous data. J Pharmacokinet Pharmacodyn 28:389-412.